bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S12 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

MMP9
Supplementary Figure 4 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 4
Supplementary Figure 2 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 2
Figure S1 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Consort diagram of ShortHER patients for the different analyses described in the present work.
Supplementary Figures from OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models
Authors: Fabre Myriam , Ferrer Cristina , Domínguez-Hormaetxe Saioa , Bockorny Bruno , Murias Laura , Seifert Oliver , Eisler Stephan A. , Kontermann Roland E. , Pfizenmaier Klaus , Lee So Young , Vivanco María dM. , López-Casas Pedro P. , Perea Sofia , Abbas Muhammad , Richter Wolfgang , Simon Laureano , Hidalgo Manuel
Published: April 2023

S1-S7 all supplementary figures with their legends: S1:Figure S1. OMTX705 binding and internalization in HT1080-WT, -FAP and CAFs S2:Weight change of mice bearing Panc 007, Lung 024 and Breast 014 tumors. S3: OMTX705 Activity in the Immunodeficient Patient Derived Xenografts (PDX) Models of Ovarian Cancer. S4: FAP immunostaining in frozen tumor samples from humanized mice bearing CTG-0860 NSCLC PDX tumor. S5: Separate fluorescent staining of human IgG, Rab7 and nuclei in OMTX705 and OMTX005 treated HT1080-FAP cells (complements the merged image of figure 4C) S6: Immunohistochemical analysis of payload, OMTX005 and OMTX705 distribution in tumors from Panc 007 model. S7: Schematic summary of findings and proposed mechanism of action of OMTX705.
Figure S3 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Glisson Bonnie S. , Leidner Rom S. , Ferris Robert L. , Powderly John , Rizvi Naiyer A. , Keam Bhumsuk , Schneider Reva , Goel Sanjay , Ohr James P. , Burton Jennifer , Zheng Yanan , Eck Steven , Gribbin Matthew , Streicher Katie , Townsley Danielle M. , Patel Sandip Pravin
Published: April 2023

Figure S3: Pharmacodynamic changes in peripheral blood
Supplementary TableS1 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Supplementary Table S1 - Statistical analysis of the survival curves in Figure 2.
Supplementary Methods from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Supplementary Methods
Figure S4 from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

Immune profiling analysis
Figure S3 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
Authors: Indraccolo Stefano , De Salvo Gian Luca , Verza Martina , Caccese Mario , Esposito Giovanni , Piga Ilaria , Del Bianco Paola , Pizzi Marco , Gardiman Marina Paola , Eoli Marica , Rudà Roberta , Brandes Alba Ariela , Ibrahim Toni , Rizzato Simona , Lolli Ivan , Zagonel Vittorina , Lombardi Giuseppe
Published: April 2023

Kaplan-Meier curves of overall survival (top) and progression free survival (bottom) according to pAMPK status
Supplemental Figure 5 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

PET detects PU-H71 retention by lymphoma. 62-year-old female with non-Hodgkin lymphoma. 124I-PU-H71 fusion PET/CT (left), CT (middle), and F-18 FDG fusion PET/CT (right) images show corresponding axial planes of chest. 124I-PU-H71 PET/CT obtained 24 hours post-injection. Mediastinal lymphomatous adenopathy (arrowhead) demonstrates PU-H71 avidity and FDG avidity.
Supplementary Figure Legends from A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Authors: Lee Hye Won , Sa Jason K. , Gualberto Antonio , Scholz Catherine , Sung Hyun Hwan , Jeong Byong Chang , Choi Han Yong , Kwon Ghee Young , Park Se Hoon
Published: April 2023

Supplementary Figure Legends
Figure S13 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Proliferation and morphology of small intestine and kidney at 3 days after i.p. administration of 148 MBq/0.357 nmol 64Cu-RaftRGD
Supplementary Figure S1 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S1
Supplementary Figure S1 from Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Authors: Davis S. Lindsey , Ionkina Anastasia A. , Bagby Stacey M. , Orth James D. , Gittleman Brian , Marcus Joshua M. , Lam Elaine T. , Corr Bradley R. , O'Bryant Cindy L. , Glode Ashley E. , Tan Aik-Choon , Kim Jihye , Tentler John J. , Capasso Anna , Lopez Kyrie L. , Gustafson Daniel L. , Messersmith Wells A. , Leong Stephen , Eckhardt S. Gail , Pitts Todd M. , Diamond Jennifer R.
Published: April 2023

Pharmacodynamic effects of alisertib and TAK-228 in patient tissue samples
Table S1 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Hyperparameter space in model tuning.
Figure S6 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S6. Cumulative incidence of death in complete remission between two consolidation cohort
Supplementary Figure 4 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S4. Combined KRASG12C and RTK inhibition improves efficacy in vivo.
Supplementary Data from EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia
Authors: Bill Marius , Pathmanathan Aparna , Karunasiri Malith , Shen Changxian , Burke Matthew H. , Ranganathan Parvathi , Papaioannou Dimitrios , Zitzer Nina C. , Snyder Katiri , LaRocco Allison , Walker Allison E. , Brannan Zachary J. , Nalin Ansel P. , Freud Aharon G. , Dikov Mikhail M. , Zhang Xiaoli , Bloomfield Clara D. , Garzon Ramiro , Dorrance Adrienne M.
Published: April 2023

Additional Supplementary Data
Supplementary Fig. S8 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Combination therapy of alectinib and ixazomib demonstrates feasibility enough to decrease tumor volume A, Percentage change in tumor volume after 28 days of treatment in A925L xenografts. B, Body weight of xenografted mice receiving indicated treatments. All data are expressed as the mean {plus minus} SE.
Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Technical performance of the MRD Assay. All samples from early stage breast cancer cohort. Includes plasma cfDNA and buffy coat gDNA samples. Samples from the same patient and probed with the same panel are represented independently. (A) On target fraction calculated from Picard CollectHsMetrics and using pct_selected_bases. (B) Coefficient of variation of duplex fragment depth across fingerprint sites. (C) Fold 80 base penalty score for duplex fragment depth across fingerprint sites. (D, E) Error rate comparison between conventional sequencing (requiring Q20 base quality and removing duplicate fragments) and our duplex sequencing with added filters (see methods). (F) Fraction of total duplexes after downsampling raw reads. We considered a sample to be saturated if it still contained at least 95% of its duplexes after downsampling to 80% of its raw reads.
Supplementary Table-4 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

4A. Classification accuracy of CMS2 samples on training data set V1 using 4-fold cross validation as function of number of genes.4B. Classification accuracy of CMS2 samples on validation data set (V2) as function of number of genes.4C. Classification accuracy CMS2 samples with out of sample(V2o) prediction set as function of number of genes. 4D. Classification accuracy CMS2 samples with TCGA dataset (RNA-seq subset) as function of number of genes.4E. Classification accuracy CMS2 samples with Affymentrix dataset (V2a) as function of number of genes.
Supplementary Figure 6 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Validation of tumor fraction confidence interval and effects of biological variability on tumor fraction inference. (A) Confidence intervals inferred from simulated data were aggregated into coverage probability for each condition and compared against theoretical coverage probability of 95% (see Methods). (B) Biological variability of clonal evolution loss was simulated by removing tumor evidence from a fraction of the fingerprint panel. Tumor fraction was calculated for simulated and original samples for comparison.
Supplementary Table-11 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Validation of CMS assay at the research molecular diagnostic laboratory. Each sample classified in to CMS subtype 1-4 or mixed (M) subtype.
Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Early stage breast cancer cohort. (A) Overview of subtype distribution of cohort as well as the timing of blood draws relative to surgery and treatment. (B) REMARK diagram of the early stage breast cancer cohort. (C) Distribution of the number of mutations tracked for each patient.
Supplementary Table-1 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Details of the data sets, including tissue type, total number of samples, total number of consensus samples are shown. FF=Flash frozen, FFPE:Formalin fixed paraffin embedded.
Supplementary Figure-1 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Algorithm showing strategy to de-velop the Nanostring based FFPE CMS classifier using Affymetrix gene expression data. FF: flash frozen, FFPE: Formalin fixed par-affin embedded, NFFPE: Nanos-tring FFPE, AFF: Flash frozen Affymetrix, GES: Gene expres-sion score, CRCSC: Colorectal cancer subtyping consortium
Supplementary Figure 11 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

MRD testing in newly diagnosed, metastatic BC patients. (A) Number of mutations detected for each patient's sample. Each patient's panel was additionally applied to healthy donors as a specificity check. (B) Tumor fraction estimates for each patient's sample over course of treatment, stratified by clinical benefit. (C) Tumor fraction fold change between first two timepoints, stratified by clinical benefit. Confidence intervals were re-calculated using the Delta Method. (D) Tumor fractions for MRD+ samples split by the minimum fingerprint size required to still detect MRD.
Supplementary Figure 3 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Heatmap showing fRMA level gene data from Affymetrix subsets in training and validation datasets.
Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Analysis of recurrently mutated genes. (A) Fraction of patients covered using the most frequent mutations in each cancer cohort. (B) Gene panel performance using TCGA breast cancer data.
Supplementary Figure S1 from Interventional Radiology for Local Immunotherapy in Oncology
Authors: Tselikas Lambros , Champiat Stephane , Sheth Rahul A. , Yevich Steve , Ammari Samy , Deschamps Frederic , Farhane Siham , Roux Charles , Susini Sandrine , Mouraud Severine , Delpla Alexandre , Raoult Thibault , Robert Caroline , Massard Christophe , Barlesi Fabrice , Soria Jean-Charles , Marabelle Aurélien , de Baere Thierry
Published: April 2023

Angular error impact on accuracy according to tumor size and depth
Figure S4 from Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Authors: Tang Lu , Wu Jianghua , Li Cheng-Gong , Jiang Hui-Wen , Xu Min , Du Mengyi , Yin Zhinan , Mei Heng , Hu Yu
Published: April 2023

Figure S4 shows pairwise comparisons of immune signatures before and after induction chemotherapy.
Supplementary Data from Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
Authors: Seymour Erlene K. , Khan Husain Yar , Li Yiwei , Chaker Mahmoud , Muqbil Irfana , Aboukameel Amro , Ramchandren Radhakrishanan , Houde Christiane , Sterbis Golbon , Yang Jay , Bhutani Divaya , Pregja Silvana , Reichel Kathy , Huddlestun Amy , Neveux Colleen , Corona Kelly , Landesman Yosef , Shah Jatin , Kauffman Michael , Shacham Sharon , Mohammad Ramzi M. , Azmi Asfar S. , Zonder Jeffrey A.
Published: April 2023

Supplementary Figure
Supplementary Figure S2 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Authors: Asleh Karama , Brauer Heather Ann , Sullivan Amy , Lauttia Susanna , Lindman Henrik , Nielsen Torsten O. , Joensuu Heikki , Thompson E. Aubrey , Chumsri Saranya
Published: April 2023

Supplementary Figure S2 depicts a representative gene expression plot
Supplementary Figure S1 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Authors: Asleh Karama , Brauer Heather Ann , Sullivan Amy , Lauttia Susanna , Lindman Henrik , Nielsen Torsten O. , Joensuu Heikki , Thompson E. Aubrey , Chumsri Saranya
Published: April 2023

Supplementary Figure S1 shows a CONSORT diagram of the study cohort
Supplementary Data S1-S9 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Authors: Asleh Karama , Brauer Heather Ann , Sullivan Amy , Lauttia Susanna , Lindman Henrik , Nielsen Torsten O. , Joensuu Heikki , Thompson E. Aubrey , Chumsri Saranya
Published: April 2023

Data S1 shows the gene content of the 770 gene panel, Data S2-S3 show the expression scores for different gene and metagenes, Data S4-S7 show univariate analyses for different genes and metagenes according to treatment arm, Data S8-S9 show functional annotation and enrichment analysis for genes associated with capecitabine benefit
Figure S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Authors: Lichtman Eben I. , Du Hongwei , Shou Peishun , Song Feifei , Suzuki Kyogo , Ahn Sarah , Li Guangming , Ferrone Soldano , Su Lishan , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Correlation of B7-H3 mRNA expression with AML features in existing datasets.
Supplementary Table 8 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows the maximum chronic GVHD organ involvement and overall score per NIH Diagnosis and Staging Criteria through full extent of study follow up on the PAC/SIR/TAC phase I trial.
Supplementary Data 1 from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Authors: Peng Zhi , Wei Jia , Wang Feng , Ying Jieer , Deng Yanhong , Gu Kangsheng , Cheng Ying , Yuan Xianglin , Xiao Juxiang , Tai Yanfei , Wang Linna , Zou Jianjun , Zhang Yanqiao , Shen Lin
Published: April 2023

Supplementary Figure 1. Kaplan-Meier curves of OS in patients with tumor PD-L1 CPS >1 and those with tumor PD-L1 CPS {less than or equal to}1. Supplementary Table 1. Current List of Participating centers and investigators. Supplementary Table 2. Subsequent anti-tumor therapies that were initiated after the last dose of the study treatment. Supplementary Table 3. Capecitabine-related AEs occurring in {greater than or equal to}10% of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib. Supplementary Table 4. Oxaliplatin-related AEs occurring in {greater than or equal to}10% of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib. Supplementary Table 5. Camrelizumab-related AEs occurring in {greater than or equal to}10% of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib. Supplementary Table 6. Apatinib-related AEs occurring in {greater than or equal to}10% of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib. Supplementary Table 7. Treatment-related SAEs of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib. Supplementary Table 8. Adverse events of special interest (AESI) regardless of attribution to study treatment of all 48 patients who received camrelizumab combined with CAPOX for followed by camrelizumab plus apatinib.
Supplementary Table 3 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows adverse events per CTCAE version 5 encountered during the PAC/SIR/TAC phase I trial.
Supplementary Figure S3 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Authors: Demetri George D. , Luke Jason J. , Hollebecque Antoine , Powderly John D. , Spira Alexander I. , Subbiah Vivek , Naumovski Louie , Chen Chris , Fang Hua , Lai Dominic W. , Yue Huibin , Polepally Akshanth R. , Purcell James W. , Robinson Randy , Sharma Padmanee , Allison James P. , Tolcher Anthony , Villalobos Victor M.
Published: April 2023

Supplementary Figure S3 shows T-cell infiltration in patients with breast cancer
Supplementary Figure 6 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

CD4+ T cell Aurora kinase A activation as a GVHD resistance mechanism. A) Graph shows frequency of CD4+, pHistone 3 serine 10+ (pH3ser10) (downstream of CD28, and parallel to mTOR) T cells (mean{plus minus} SEM) at day +21 among patients treated on dose level 1 or dose level 2 of the phase I trial compared to baseline control values. B) Graph depicts the frequency (mean {plus minus} SEM) of CD4+, pH3ser10+ T cells recovered from NSG spleens at day +14, following transplantation with human PBMCs and then treated with vehicle, pacritinib, 531-201, sirolimus, pacritinib plus sirolimus, or 531-201 plus sirolimus for 2 weeks.
Supplementary Figure 1 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

Impact of JAK2 or STAT3 inhibition plus mTOR blockade on DC-allostimulated human T cell production of IFNγ, IL-13, and GM-CSF. 5-day alloMLRs were treated with DMSO vehicle control, pacritinib 1.25μM, S3I-201 5μM, sirolimus 10ng/ml, pacritinib plus sirolimus, or S3I-201 plus sirolimus. The graphs show the concentrations of A) IFNγ, B) IL-13, and C) GM-CSF (mean{plus minus}SEM) as measured in the supernatants of the culture medium by a cytokine multiplex assay.
Table S5 from Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains
Authors: Klein Sebastian , Quaas Alexander , Quantius Jennifer , Löser Heike , Meinel Jörn , Peifer Martin , Wagner Steffen , Gattenlöhner Stefan , Wittekindt Claus , von Knebel Doeberitz Magnus , Prigge Elena-Sophie , Langer Christine , Noh Ka-Won , Maltseva Margaret , Reinhardt Hans Christian , Büttner Reinhard , Klussmann Jens Peter , Wuerdemann Nora
Published: April 2023

HPV-ps multivariate analysis of Giessen OPSCC, Cologne OPSCC and TCGA HNSCC
Table S4 from Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains
Authors: Klein Sebastian , Quaas Alexander , Quantius Jennifer , Löser Heike , Meinel Jörn , Peifer Martin , Wagner Steffen , Gattenlöhner Stefan , Wittekindt Claus , von Knebel Doeberitz Magnus , Prigge Elena-Sophie , Langer Christine , Noh Ka-Won , Maltseva Margaret , Reinhardt Hans Christian , Büttner Reinhard , Klussmann Jens Peter , Wuerdemann Nora
Published: April 2023

Patient characteristics and contributions training cohorts
Table S2 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Patients characteristics in ICI discovery and validation cohorts
Table S2 from Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains
Authors: Klein Sebastian , Quaas Alexander , Quantius Jennifer , Löser Heike , Meinel Jörn , Peifer Martin , Wagner Steffen , Gattenlöhner Stefan , Wittekindt Claus , von Knebel Doeberitz Magnus , Prigge Elena-Sophie , Langer Christine , Noh Ka-Won , Maltseva Margaret , Reinhardt Hans Christian , Büttner Reinhard , Klussmann Jens Peter , Wuerdemann Nora
Published: April 2023

Patient characteristics OPSCC Cologne cohort
Table S1 from Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains
Authors: Klein Sebastian , Quaas Alexander , Quantius Jennifer , Löser Heike , Meinel Jörn , Peifer Martin , Wagner Steffen , Gattenlöhner Stefan , Wittekindt Claus , von Knebel Doeberitz Magnus , Prigge Elena-Sophie , Langer Christine , Noh Ka-Won , Maltseva Margaret , Reinhardt Hans Christian , Büttner Reinhard , Klussmann Jens Peter , Wuerdemann Nora
Published: April 2023

Patient characteristics OPSCC Giessen cohort
Supplementary Legend from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Legend
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 3: (A) PFS and (B) OS of patients based on lines of prior therapies (<=2 vs. >=3)
Figure S3 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Comparison of progression free survival and overall survival between the discovery and validation cohorts
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 5: (A) PFS and (B) OS of patients based on tumor histology (colorectal adenocarcinomas vs. all others).
Table S5 from An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Authors: Chen Yue , Li Zhi-Yong , Zhou Guan-Qun , Sun Ying
Published: April 2023

The gene set enrichment analysis between the IRGPI-high and IRGPI-low subgroups
Table S4 from An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Authors: Chen Yue , Li Zhi-Yong , Zhou Guan-Qun , Sun Ying
Published: April 2023

The IRGPI characteristics adjusted by other clinical factors
Supplementary Figure 1-8 from An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Authors: Chen Yue , Li Zhi-Yong , Zhou Guan-Qun , Sun Ying
Published: April 2023

SUPPLEMENTARY FIGURES
Supplementary Table 3 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

Comparison of CLIA results and sequencing results for five tumor specimens and three PBMCs.
Supplementary Table S2 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Table S2. Melanoma cell lines investigated for response to IFNγ
Supplementary Table S1 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Table S1. List of IFNγ pathway genes investigated for TCGA analysis
Supplementary Methods and Legends from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Supplementary Methods and Legends
Supplementary Figure S2 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Figure S2. JAK2 restoration in IFNγ-nonresponsive Colo857 confers resistance against HSV1-dICP0
Supplementary Figure S1 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Figure S1. Melanoma cell lines are responsive to type I and II IFNs induction
Supplementary Data from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
Authors: DeLucia Diana C. , Cardillo Thomas M. , Ang Lisa , Labrecque Mark P. , Zhang Ailin , Hopkins James E. , De Sarkar Navonil , Coleman Ilsa , da Costa Rui M. Gil , Corey Eva , True Lawrence D. , Haffner Michael C. , Schweizer Michael T. , Morrissey Colm , Nelson Peter S. , Lee John K.
Published: April 2023

Supplementary Figures and Supplementary Materials and Methods
Supplementary Data File from High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Authors: Strell Carina , Folkvaljon Dick , Holmberg Erik , Schiza Aglaia , Thurfjell Viktoria , Karlsson Per , Bergh Jonas , Bremer Troy , Akslen Lars A. , Wärnberg Fredrik , Östman Arne
Published: April 2023

Supplementary data file with extended Materials and Methods, Supplementary Tables 1-6 and Supplementary Figures 1-3
Supplementary Figure S3 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Authors: Noordhoek Iris , Treuner Kai , Putter Hein , Zhang Yi , Wong Jenna , Meershoek-Klein Kranenbarg Elma , Duijm-de Carpentier Marjolijn , van de Velde Cornelis J.H. , Schnabel Catherine A. , Liefers Gerrit-Jan
Published: April 2023

Distribution of ER, PR and HER2 expression among BCI (H/I) groups by prior endocrine therapy.
Supplementary Data from MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Authors: Wirsching Hans-Georg , Roelcke Ulrich , Weller Jonathan , Hundsberger Thomas , Hottinger Andreas F. , von Moos Roger , Caparrotti Francesca , Conen Katrin , Remonda Luca , Roth Patrick , Ochsenbein Adrian , Tabatabai Ghazaleh , Weller Michael
Published: April 2023

Note S1, Figure S1-S4, Table S1-S3
Table S3 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Gandhi Shipra , Pandey Manu R. , Attwood Kristopher , Ji Wenyan , Witkiewicz Agnieszka K. , Knudsen Erik S. , Allen Cheryl , Tario Joseph D. , Wallace Paul K. , Cedeno Carlos D. , Levis Maria , Stack Suzanne , Funchain Pauline , Drabick Joseph J. , Bucsek Mark J. , Puzanov Igor , Mohammadpour Hemn , Repasky Elizabeth A. , Ernstoff Marc S.
Published: April 2023

Percentage of cells (m-MDSC, PMN-MDSC, T regulatory cells, T helper cells, cytotoxic T-cells, PD-L1+ melanoma cells, activated, partially exhausted and exhausted CD8+ T-cells) in archival tissue biopsies for 8/9 patients in the regions of interest selected for the analysis
Figure S3 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Authors: Singh Anju , Daemen Anneleen , Nickles Dorothee , Jeon Sang-Min , Foreman Oded , Sudini Kuladeep , Gnad Florian , Lajoie Stephane , Gour Naina , Mitzner Wayne , Chatterjee Samit , Choi Eun-Ji , Ravishankar Buvana , Rappaport Amy , Patil Namrata , McCleland Mark , Johnson Leisa , Acquaah-Mensah George , Gabrielson Edward , Biswal Shyam , Hatzivassiliou Georgia
Published: April 2023

Fig. S3, related to Fig. 3.
Figure S2 from NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Authors: Singh Anju , Daemen Anneleen , Nickles Dorothee , Jeon Sang-Min , Foreman Oded , Sudini Kuladeep , Gnad Florian , Lajoie Stephane , Gour Naina , Mitzner Wayne , Chatterjee Samit , Choi Eun-Ji , Ravishankar Buvana , Rappaport Amy , Patil Namrata , McCleland Mark , Johnson Leisa , Acquaah-Mensah George , Gabrielson Edward , Biswal Shyam , Hatzivassiliou Georgia
Published: April 2023

Fig. S2, related to Fig. 2.
Figure S4 from TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma
Authors: Yang Zhi-Zhang , Kim Hyo Jin , Wu Hongyan , Jalali Shahrzad , Tang Xinyi , Krull Jordan E. , Ding Wei , Novak Anne J. , Ansell Stephen M.
Published: April 2023

(A) Kaplan-Meier curves for overall (OS) or event-free survival (EFS) of FL patients by TIGIT RNA expression level. (B) Kaplan-Meier curves for OS or EFS of FL patients who were observed and received no treatment.
Figure S3 from TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma
Authors: Yang Zhi-Zhang , Kim Hyo Jin , Wu Hongyan , Jalali Shahrzad , Tang Xinyi , Krull Jordan E. , Ding Wei , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Graph showing percentages of non-Treg/TFH TIGIT+ T subsets in patients who achieved or failed EFS24.
Supplementary Figure 1 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Authors: Varga Andrea , Soria Jean-Charles , Hollebecque Antoine , LoRusso Patricia , Bendell Johanna , Huang Shih-Min A. , Wagle Marie-Claire , Okrah Kwame , Liu Lichuan , Murray Elaine , Sanabria-Bohorquez Sandra M. , Tagen Michael , Dokainish Hatem , Mueller Lars , Burris Howard
Published: April 2023

Supplemental Figure 1. Suppression of MAPK pathway activation at the RP2D in colorectal cancer and pancreatic cancer patients. GDC-0994 modulates MAPK pathway-regulated gene transcription at the RP2D. Note: there were no partial responses in this group of patients.
Figure S1 from TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma
Authors: Yang Zhi-Zhang , Kim Hyo Jin , Wu Hongyan , Jalali Shahrzad , Tang Xinyi , Krull Jordan E. , Ding Wei , Novak Anne J. , Ansell Stephen M.
Published: April 2023

TIGIT expression on cell subpopulation
Supplementary Table S1 from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Authors: Arena Sabrina , Corti Giorgio , Durinikova Erika , Montone Monica , Reilly Nicole M. , Russo Mariangela , Lorenzato Annalisa , Arcella Pamela , Lazzari Luca , Rospo Giuseppe , Pagani Massimiliano , Cancelliere Carlotta , Negrino Carola , Isella Claudio , Bartolini Alice , Cassingena Andrea , Amatu Alessio , Mauri Gianluca , Sartore-Bianchi Andrea , Mittica Gloria , Medico Enzo , Marsoni Silvia , Linnebacher Michael , Abrignani Sergio , Siena Salvatore , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

Supplementary Table S1